Management of Cerebral Venous Thrombosis Due to Adenoviral COVID‐19 Vaccination

Cerebral venous thrombosis (CVT) caused by vaccine‐induced immune thrombotic thrombocytopenia (VITT) is a rare adverse effect of adenovirus‐based severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) vaccines. In March 2021, after autoimmune pathogenesis of VITT was discovered, treatment recommendations were developed. These comprised immunomodulation, non‐heparin anticoagulants, and avoidance of platelet transfusion. The aim of this study was to evaluate adherence to these recommendations and its association with mortality.

Thalia Shoshana Field | J. Ferro | A. Gutschalk | T. Bartsch | J. Payen | Á. Cervera | M. Wittstock | J. Schouten | T. Tatlisumak | C. Cordonnier | J. Putaala | F. Bonneville | S. Timsit | E. Kristoffersen | A. Günther | S. Middeldorp | S. Nagel | M. Kruip | Francesco Grillo | R. Kern | S. Coutts | A. Aujayeb | D. Michalski | C. Jacobi | C. Zanferrari | E. de Maistre | A. Tiede | T. Kleinig | E. V. van Gorp | D. van de Beek | T. Geeraerts | J. K. Kremer Hovinga | R. Lemmens | D. Blacquiere | K. Jood | G. Frisullo | J. Coutinho | F. Vuillier | S. Hiltunen | S. Poli | K. Krzywicka | K. Garambois | M. Petruzzellis | P. Reiner | K. Ng | B. Buck | J. Brodard | V. Palma | J. Burrow | D. Aguiar de Sousa | M. Skjelland | S. Murphy | E. Johansson | E. Cuadrado-Godia | D. Bougon | M. Bandettini di Poggio | H. Katzberg | C. Vayne | A. Negro | N. Raposo | T. Gattringer | M. Heldner | Alina Buture | A. Medina | J. Zimmermann | Mayte Sánchez van Kammen | M. Wiedmann | A. Ciccone | G. Franchineau | K. Althaus | J. Pelz | T. Karapanayiotides | Marcel M. Levi | A. Scutelnic | D. Zimatore | A. Mengel | Fabrizio Giammello | Felix J. Bode | C. Tracol | Simerpreet Bal | C. Legault | A. Elkady | B. Chew | M. Ghiasian | M. Arnold | E. Lindgren | S. Chatterton | Anita van de Munckhof | Åslög Hellström Vogel | A. Tawa | Cristina Soriano | F. Maier | Marie Dubois | Robert Kahnis | T. Cox | V. Dizonno | A. Cervera | Joshua Mbroh | A. Devroye | M. Wronski | S. Schoenenberger | Marjolaine Martin | Carlos Garcia Esperon | Miguel S Miranda | João Fernandes | Anemon Puthuppallil Philip | M. Sánchez van Kammen | F. Bode | Annerose Mengel | Theodoros Karapanayiotides | J. Mbroh | D. S. Zimatore | A. van de Munckhof | Miguel Miranda | C. Garcia Esperon

[1]  J. Ferro,et al.  Cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia after a second ChAdOx1 nCoV-19 dose , 2022, Blood.

[2]  S. Lamin,et al.  Mechanical Thrombectomy for Treatment of Cerebral Venous Sinus Thrombosis in Vaccine-Induced Immune Thrombotic Thrombocytopenia , 2021, American Journal of Neuroradiology.

[3]  A. Zwinderman,et al.  Age-Stratified Risk of Cerebral Venous Sinus Thrombosis After SARS-CoV-2 Vaccination , 2021, Neurology.

[4]  A. Greinacher,et al.  Vaccine‐induced immune thrombotic thrombocytopenia (VITT): Update on diagnosis and management considering different resources , 2021, Journal of Thrombosis and Haemostasis.

[5]  Thalia Shoshana Field,et al.  Characteristics and Outcomes of Patients With Cerebral Venous Sinus Thrombosis in SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia. , 2021, JAMA neurology.

[6]  J. Ferro,et al.  Declining mortality of cerebral venous sinus thrombosis with thrombocytopenia after SARS‐CoV‐2 vaccination , 2021, European journal of neurology.

[7]  J. Dogné,et al.  Fatal exacerbation of ChadOx1-nCoV-19-induced thrombotic thrombocytopenia syndrome after initial successful therapy with intravenous immunoglobulins - a rational for monitoring immunoglobulin G levels. , 2021, Haematologica.

[8]  G. Ambler,et al.  Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis , 2021, The New England journal of medicine.

[9]  J. Ferro,et al.  Post‐SARS‐CoV‐2‐vaccination cerebral venous sinus thrombosis: an analysis of cases notified to the European Medicines Agency , 2021, European journal of neurology.

[10]  J. Ferro,et al.  European stroke organization interim expert opinion on cerebral venous thrombosis occurring after SARS-CoV-2 vaccination , 2021, European stroke journal.

[11]  U. Ziemann,et al.  The use of IV immunoglobulin in the treatment of vaccine-induced immune thrombotic thrombocytopenia , 2021, Blood.

[12]  E. Woo,et al.  US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021. , 2021, JAMA.

[13]  J. Bussel,et al.  SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia , 2021, The New England journal of medicine.

[14]  D. Goldblatt,et al.  Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination , 2021, The New England journal of medicine.

[15]  Andreas Greinacher,et al.  Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination , 2021, The New England journal of medicine.

[16]  Fridtjof Lund-Johansen,et al.  Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination , 2021, The New England journal of medicine.

[17]  J. Oldenburg,et al.  Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH , 2021, Hämostaseologie.

[18]  M. Jit,et al.  Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment , 2021, The Lancet.

[19]  N. Mohr,et al.  Association of admission clinical predictors and functional outcome in patients with Cerebral Venous and Dural Sinus Thrombosis , 2019, Clinical Neurology and Neurosurgery.

[20]  D. Khullar,et al.  Association Between Teaching Status and Mortality in US Hospitals , 2017, JAMA.

[21]  Gustavo Saposnik,et al.  Diagnosis and Management of Cerebral Venous Thrombosis: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2011, Stroke.

[22]  S. Schulman,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.

[23]  M. Cowan,et al.  American Heart Association. , 2018, P & T : a peer-reviewed journal for formulary management.